Sustained Epstein-Barr virus detection in paediatric liver transplantation. Insights into the occurance of late PTLD

Liver Transplantation

Volumn 13, Issue 3, 2007, Pages 343-348

  D'Antiga, Lorenzo ^a   Del Rizzo, Monica ^a   Mengoli, Carlo ^a   Cillo, Umberto ^a   Guariso, Graziella ^a   Zancan, Lucia ^a  

^a UNIVERSITY OF PADOVA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ACICLOVIR; AZATHIOPRINE; CORTICOSTEROID; CYCLOSPORIN A; IMMUNOGLOBULIN G; IMMUNOGLOBULIN M; METHYLPREDNISOLONE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISOLONE; TACROLIMUS; VIRUS CAPSID ANTIGEN;

ACUTE GRAFT REJECTION; ADOLESCENT; ARTICLE; CHILD; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG BLOOD LEVEL; EPSTEIN BARR VIRUS; FEMALE; FOLLOW UP; HERPES VIRUS INFECTION; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; INFANT; LIVER TRANSPLANTATION; LYMPHOPROLIFERATIVE DISEASE; MALE; MONONUCLEAR CELL; PRIORITY JOURNAL; RETROSPECTIVE STUDY; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; VIRUS DETECTION; VIRUS INFECTION; VIRUS LOAD;

ADOLESCENT; ANTIBODIES, VIRAL; CHILD; CHILD, PRESCHOOL; EPSTEIN-BARR VIRUS INFECTIONS; FEMALE; GRAFT REJECTION; HERPESVIRUS 4, HUMAN; HUMANS; IMMUNOSUPPRESSION; INFANT; LIVER TRANSPLANTATION; LYMPHOPROLIFERATIVE DISORDERS; MALE; MONITORING, IMMUNOLOGIC; RETROSPECTIVE STUDIES; TIME FACTORS; VIRAL LOAD;

EID: 33947417762     PISSN: 15276465     EISSN: 15276473     Source Type: Journal    
DOI: 10.1002/lt.20958     Document Type: Article

References (28)

1. Epstein MA, Achong BG, Barr, YM. Virus particles in cultured lymphoblasts from Burkitt's lymphoma. Lancet 1964; 1:702-703.
2. Cohen JL. Epstein-Barr virus infection. N Engl J Med 2000: 343:481-492.
3. Paya CV, Fung JJ, Nalesnik MA, Kielt E, Green M, Gores G, et al. Epstein-Barr virus-induced posttransplant lymphoproliferative disorders. Transplantation 1999;68:1517-1525.
4. R. D. Holmes and R. J, Sokol. Epstein-Barr virus and post-transplant lymphoproliferative, disease. Pediatr Transplantation 2002;6:456-464.
5. Ho M, Jaffe R, Miller G, Breinig MR, Dummer JS, Makowka L, et al. The frequency of Epstein Barr virus infection and associated lymphoproliferative syndrome after transplantation and its manifestations in children. Transplantation 1988:45:719-727.
6. Guthery SL, Heubi JE, Bucuvalas JC, Gross TG, Ryckman FC, Alonzo MH, et al. Determination of risk factors for Epstein-Barr virus-associated posttransplant lymphoproliferative disorder in pediatric liver transplant recipients using objective case ascertainment. Transplantation 2003; 15:987-993.
7. Riddler SA, Breinig MC, McKnight JLC. Increased levels of circulating Epstein-Barr virus (EBV)-infected lymphocytes and decrreased EBV nuclear antigen antibody responses are associated with the development of posttransplant lymphoproliferative disease in solid-organ transplant patents. Blood 1994;84:972-984
8. Lee TC, Savoldo B. Rooney CM, Heslop HE, Gee AP, Caldwell Y, et al. Quantitative EBV viral loads and immunosuppression alterations can decrease PTLD incidence in pediatric liver transplant recipients. Am J Transplant 2005;5: 2222-2228
9. D'Antiga L., Dhawan A, Portmann B, Francavilla R, Rein M, Heaton N, et al. Late cellular rejection in paediatric liver transplantation. Aethiology and outcome. Transplantation 2002:73:80-84.
10. Kogan-Libermann D, Burroughs M, Emre S, Moscona A, Shnelder BL. The role of quantitative Epstein-Barr virus, polymerase chain reaction and pre-emptive immunosuppression reduction in pediatric liver transplantation: a preliminary experience. J Pediatr Gastroenterol Nutr 2001;33:445-449.
11. Jenson H, McIntosh K, Pitt J, Husak S. Tan M, Bryson Y, et al. Natural history of primary Epstein-Barr virus, infection in children of mothers infected with human immunodeficiency virus type 1. J Infect Dis 1999;179: 1395-1404.
12. Biasolo MA, Calistri A, Cesaro S, Gentile, G, Mengoli C, Palu G. Case report: kinetics of Epstein-Barr virus load in a bone marrow transplant patient with no sign of lymphoproliferative disease. J Med Virol 2003;69:220-224.
13. McDiarmid SV. Management of the pediatric liver transplant patient. Liver Transpl 2001;7:S77-S86.
14. Fridell JA, Jain A, Reyes J. Biederman R, Green M, Sindhi R, Mazariegos GV. Causes of mortality beyond 1 year after primary pediatric liver transplant under tocrolimus. Transplantation 2002;74:1721-1724.
15. Smets F, Sokal EM. Epstein-Barr virus-related lymphoproliferation in children after liver transplant: Role of immunity, diagnosis. and management. Pediatr Transplant 2002;6:280-287.
16. Randhawa PS, Jaffe R, Demetris AJ, Nalesnik M, Starzl TE, Chen YY, Weiss LM. Expression of Epstein-Barr virus-encoded small RNA (by the EBER-1 gene) in liver specimens from transplant recipients with post-transplantation lymphoproliferative disease. N Engl J Med 1992;327: 1710-1714.
17. Starzl TE, Nalesnik MA, Porter KA, Ho M, Iwatsuki S, Griffith BP et al. Reversibility of lymphomas and lymphoproliferative lesions developing under cyclosporin-steroid therapy. Lancet 1984:1:583-587.
18. Green M, Kaufmann M, Wilson J, Reyes J. Comparison of intravenous ganciclovir followed by oral acyclovir with intravenous ganciclovir alone for prevention of cytomegalovirus and Epstein-Barr virus disease after liver transplantation in children. Clin Infect Dis 1997;25: 1344-1349.
19. McDiarmid SV, Jordan S, Kim GS, Toyoda M, Goss JA, Vargas JH, et al. Prevention and pre-emptive therapy of posttransplant lymphoproliferative disease in pediatric liver recipients. Transplantation 1998;66:1601-1611.
20. Serinet MO, Jacquemin E, Habes D, Debray D. Fabre M, Bernard O. And-CD20 monoclonal antibody (Rituximab) treatment for Epstein-Barr virus-associated, B-cell lymphoproliferative disease in pediatric liver transplant recipients. J Pediatr Gastroenterol Nutr 2002;34:389-393.
21. Benkerrou M, Jois J-P, Leblond V, Durandy A, Sutton L, Bordigoni P, et al. Anti-B-cell monoclonal antibody treatment of severe posttransplant B-lymphoproliferative disorder: prognostic factors and long-term outcome. Blood 1998;92:3137-3147.
22. Savoldo B, Rooney CM, Quiros-Tejeira RE, Caldwell Y, Wagner HJ, Lee T, et al. Cellular immunity to Epstein-Barr virus in liver transplant recipients treated with rituximab for post-transplant lymphoproliferative disease. Am J Transplant 2005;5:566-572.
23. Rooney CM, Smith CA, Ng CY, Loftin SK, Sixbey JW, Gan Y, et al. Infusion of cytotoxic T cells for the prevention and treatment of Epstein-Barr virus-induced lymphoma in allogenic transplant recipients. Blood 1998; 92:1549-1555.
24. Comoli P, Maccario R, Locatelli F, Valente U, Basso S, Garaventa, A, et al. Treatment of EBV-related post-renal transplant lymphoproliferative disease with a tailored regimen including EBV-specific T cells. Am J Transplant 2005;5:1415-1422.
25. Smets, F, Bodeus, M, Goubau, P, Reding R, Otte JB, Buts JP, Sokal EM. Characteristics of Epstein-Barr virus primary infection in pediatric liver transplant recipients. J Hepatology 2000;32:100-104.
26. Rowe DT, Qu L, Reyes J, Jabbour N, Yunis E, Putnam P, et al. Use of quantitative competitive PCR to measure Epstein-Barr virus genome load in the peripheral blood of pediatric transplant patients with lymphoproliferative disorder. J Clin Microbiol 1997;35:1612-1615.
27. Thorley-Lawson DA, Gross A. Persistence of the Epstein-Barr virus and the origns of associated lymphomas. N Engl J Med. 2004;350:1328-1337.
28. Bingler MA, Miller SA, Michaels MG, Green M, et al. Chronic high Epstein-Barr virus load carrier state and risk for late onset PTLD/malignant lymphoma. Pediatr Transpl 2005:9(suppl 6);A167.